For nearly two years, compounding pharmacies filled a critical gap in the GLP-1 medication market. During the prolonged semaglutide shortage, 503A compounding pharmacies and 503B outsourcing facilities legally produced compounded versions of semaglutide, offering patients access at a fraction of the brand-name cost. That era is now over.
The Shortage Is Resolved, the Crackdown Begins
In February 2025, the FDA officially declared the semaglutide shortage resolved. Novo Nordisk, the manufacturer of Ozempic and Wegovy, confirmed it could meet market demand. Under the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may only produce copies of FDA-approved drugs when those drugs are listed on the official shortage list. With semaglutide removed from that list, the legal basis for compounding disappeared.
The FDA set clear deadlines. Section 503A pharmacies, the traditional compounding pharmacies that prepare medications based on individual prescriptions, were given until April 22, 2025 to cease compounding semaglutide. Section 503B outsourcing facilities, which produce compounded drugs in larger batches without patient-specific prescriptions, received a slightly longer runway until May 22, 2025.
The Cost Divide
The financial impact on patients is significant. Compounded semaglutide typically cost between $100 and $300 per month, depending on dose and provider. Brand-name Ozempic and Wegovy carry list prices exceeding $1,000 per month. For patients without insurance coverage or those whose plans exclude GLP-1 medications for weight management, the gap is enormous.
Millions of Americans had turned to compounded semaglutide not only because of the shortage but because it was affordable. Telehealth platforms and direct-to-consumer pharmacies built entire business models around compounded GLP-1 prescriptions, making weight-loss treatment accessible to a much broader population.
Industry Pushback and Legal Challenges
The Outsourcing Facilities Association (OFA) responded with a lawsuit against the FDA, calling the enforcement action "reckless and arbitrary." The OFA argued that the FDA's shortage determination process lacked transparency and that patients would be harmed by the abrupt cutoff. The legal challenge raised questions about whether the FDA adequately considered patient access before declaring the shortage resolved.
Hims & Hers Health, one of the largest telehealth platforms offering compounded semaglutide, saw its stock price decline sharply following the announcement. The company had generated substantial revenue from its compounded GLP-1 programs and faced immediate pressure to pivot its business strategy.
What This Means for Canadian Patients
Canada operates under a different regulatory framework, but the ripple effects are relevant. Canadian patients who purchased compounded semaglutide from US-based telehealth platforms will lose access to those products. Health Canada maintains its own drug shortage database and compounding regulations through provincial pharmacy colleges.
Canadian pharmacies that compound medications follow provincial regulations rather than FDA rules. However, the global supply dynamics for semaglutide's active pharmaceutical ingredient affect Canadian compounders as well. Novo Nordisk's patent protections and supply agreements create constraints regardless of jurisdiction.
The Broader GLP-1 Landscape
The FDA's enforcement action highlights an ongoing tension in pharmaceutical regulation: the balance between protecting brand-name drug patents and ensuring patient access. GLP-1 receptor agonists have proven effective for both diabetes management and weight loss, generating unprecedented demand. Novo Nordisk and Eli Lilly, the two primary manufacturers, reported record revenues in 2024.
For patients currently on compounded semaglutide, the transition options include switching to brand-name products, exploring manufacturer savings programs, or discussing alternative GLP-1 medications with their healthcare providers. Some patients may qualify for tirzepatide (Mounjaro/Zepbound), which remains on the FDA shortage list and can still be legally compounded.
Looking Ahead
The compounding debate is far from settled. As new GLP-1 medications enter the market and patent expirations approach in the coming years, the competitive landscape will shift. Until then, patients and providers must navigate a system where regulatory compliance and affordability often pull in opposite directions.
At PlusVirtual, we continue to monitor GLP-1 availability and pricing to help Canadian patients access the medications they need through legitimate, regulated channels.